program - pace-cme · 2016. 12. 24. · centara grand & bangkok convention centre at...

P R O G R A M

asian interchangeon diabetes

30–31 July in Bangkok, Thailand

Venue

Centara Grand at Central World

2 | A S I A N I N T E R C H A N G E O N D I A B E T E S

ACROSS T2D

Your gateway to the international expert forum for Type 2 Diabetes

ACROSS T2D is a global academy for cardiovascular risk, outcomes and safety studies in Type 2

Diabetes (T2D). It has been established as a collaboration with leading international experts to

provide education and share best clinical practice among professionals who manage patients with

Type 2 Diabetes (T2D). For more information visit us at: www.across-t2d.com

Physicians’ Academy for Cardiovascular Education (PACE-CME) foundation

The rationale for establishing the PACE foundation, the Physicians’ Academy for Cardiovascular

Education foundation comes from the recognition that physician education plays an increasingly

important role in our efforts to reduce the burden of cardiovascular disease and diabetes. The goal

of PACE is to help physicians assimilate the proven findings of scientific research into the day-to-

day practice of clinical medicine, all in the interest of improving outcomes in patients.

The mission of PACE-CME is to improve the cardiovascular health of patients by providing an

international forum for the review, exchange and assimilation of new important data underlying

cardiovascular disease and diabetes and accelerate the translation of this information into clinical

practice. For more information visit us at: www.PACE-CME.org

BANGKOK2016JULY 30 & 31

3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 3

Bangkok, July 2016

On behalf of Boehringer Ingelheim (S) Pte Ltd, ACROSS T2D and the PACE foundation,

we welcome you to the 3rd Asian Interchange on Diabetes:

Innovation in T2DM: How will novel interventions impact clinical care?

Diabetes Clinical Innovation

Diabetes and Cardiovascular disease (CVD) have continued to rise to epidemic

proportions throughout the world, despite improvements in our understanding and

management of these diseases. Patients with diabetes have a high lifetime CVD risk, thus

management of these patients should not only focus on control of glycaemia but also

address CV risk factors. The conventional approach to managing CVD is aimed at treating

the major CV risk factors: diabetes, hypertension, dyslipidaemia, obesity and smoking as

separate entities, without understanding how a combination of these can multiply the CV

risk. Furthermore, a considerable treatment gap between evidence and practice exists

because guidelines recommendations are not adequately implemented. Newer classes

of glucose lowering drugs have been developed in recent years. Several ongoing and

recently published trials provide guidance that the incretin axis directly or indirectly can

lower CVD risk in diabetes. Recently trials with DPP4 inhibitors suggested that oral gliptin

therapy is safe in CVD but did not lower CVD risk in the short term. Results of longer term

studies with other DPP4 inhibitors and GLP-1 analogue therapies are awaited. Novel data

from the new class of SGLT2 inhibitors showed in the EMPA-REG OUTCOME trial positive

outcomes on the primary endpoint, which included a reduction in CV mortality. During

this Asian Interchange on Diabetes you will receive a balanced review on how all these

novel developments might impact your clinical practice in managing your patients with

T2DM.

Asian Interchange on Diabetes – PACE-CME & ACROSS T2D

This Asian Interchange on Diabetes is in collaboration with PACE-CME (Physicians’

Academy for Cardiovascular Education) and ACROSS T2D (Academy for Cardiovascular

Risk, Outcomes and Safety Studies in Type 2 Diabetes). The mission of PACE-CME is

to improve the cardiovascular health of patients by providing an international forum for

the review, exchange and assimilation of new important data underlying cardiovascular

disease and diabetes and accelerate the translation of this information into clinical

practice.

We wish you an interesting and stimulating meeting.

PACE-CME Foundation


Program itinerary

Friday July 29, 2016

Arrivals All day

Saturday July 30, 2016

Scientific session 08:30 – 10:30 hrs Ballroom A&B

Coffee break 10:30 – 11:00 hrs Foyer


Lunch 12:30 – 13:30 hrs Delegates Café

Workshops 13:30 – 15:00 hrs Ballroom A&B, Lotus Suite 11,

Lotus Suite 12

Sunday July 31, 2016


Coffee break 11:00 – 11:30 hrs Foyer

Optional lunch 11:30 – 13:00 hrs Delegates Café

Departures Lobby


Address

Centara Grand & Bangkok Convention Centre at CentralWorld

999/99 Rama 1 Road, Pathumwan

Bangkok 10330, Thailand

Check in time: 14:00 hrs

Check out time: 12:00 hrs

Breakfast: 06:00 – 10:30 hrs, The World Restaurant, level 24


Educational Agenda

Saturday, July 30, 2016

Co-chairmen:

Sompongse Suwanwalaikorn, MD – Chulalongkorn University, Bangkok, Thailand

David Fitchett, MD – University of Toronto, Canada

08:30 – 08:40 Introduction and educational objectives

08:40 – 09:05 Diabetes in Asia: What is different from the west?

Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine,

Bangkok, Thailand

09:05 – 09:40 Management of hyperglycemia in type 2 diabetes:

Update on novel trends and developments

Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA

09:40 – 10:15 Need for ongoing clinical innovation in management of T2DM:

A closer look at the development process of new entities

Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

10:15 – 10:30 Panel discussion

All faculty

10:30 – 11:00 Coffee break

Co-chairmen:

Sompongse Suwanwalaikorn, MD – Chulalongkorn University, Bangkok, Thailand

Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA

11:00 – 11:35 Diabetes and Cardiovascular Disease:

A review of new outcome data impacting practice

David Fitchett, MD – University of Toronto, Canada

11:35 – 12:10 Understanding Diabetes Kidney Disease:

What are the best options for clinical management?

Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland


12:10 – 12:30 Open forum

All faculty

12:30 – 13:30 Lunch break

WORKSHOPS - CASE DISCUSSIONS

13:30 – 15:00 The clinical challenge of innovations in T2DM

management

International experts will discuss based on practical case studies the

implications of novel developments for patient care

Sunday, July 31

MEET THE EXPERTS

09:00 – 09:30 Update on DPP4 inhibition in T2DM: Implications from

recent and ongoing trials

Richard E. Pratley, MD

09:30 – 09:55 CV Protection in the EMPA-REG OUTCOME Trial:

A ‘Thrifty Substrate’ Hypothesis

Michael Mark, MD

09:55 – 10:25 Update on SGLT2 inhibition in T2DM: A closer look at

EMPA-REG OUTCOME

David Fitchett, MD

10:25 – 11:00 DEBATE

Individualizing the Management of T2DM: who and how?

Based on provocative statements reflecting current and future

management of T2DM in Asia the panel will have an interactive

debate

11:00 Coffee break & end of program


David Fitchett

Lectures:

• Diabetes and Cardiovascular Disease: A review of new outcome

data impacting practice

• Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG

OUTCOME

Dr. David Fitchett MA MB BChir MD(Cantab) MRCP(UK) FRCP(C) FACC FESC

graduated from Cambridge University in the UK in 1970, and continued

his clinical training at The Middlesex Hospital Medical School, London. His

cardiology training was at The Brompton and Hammersmith Hospitals where

he completed his MD thesis in Clinical and Experimental Studies of Heart

Muscle Disorders. In 1978 he went to The Royal Victoria Hospital, Montreal

where he was director of the CCU and medical director of the cardiac

transplant program.

He is a fellow of the American College of Cardiology, The European Society

of Cardiology and of the Royal College of Physicians of Canada.

In 1997 he came to St Michael’s Hospital in Toronto as Director of the Cardiac

ICU. He remained in that role until 2008.

Dr Fitchett has over 230 reviewed publications, abstracts, and book

chapters. He is a reviewer for many journals including the New England

Journal of Medicine, Circulation, American Heart Journal, Nature Medicine,

and the Canadian Journal of Cardiology. His research interests are clinical

trials in acute coronary syndromes, and the impact of diabetes and metabolic

syndrome on heart disease.

He is the chair of the macrovascular section of the Canadian Diabetes

Guidelines. He is on the steering and on data and safety committees for a

number of international clinical trials.

Currently Dr Fitchett is an Associate Professor of Medicine at the University

of Toronto and a Staff Cardiologist at St Michael’s Hospital.

University of Toronto,

Toronto, Canada


Sompongse Suwanwalaikorn

Associate Professor Sompongse Suwanwalaikorn is Deputy Medical Service

Director in the Division of Endocrinology and Metabolism, Department of

Medicine at Chulalongkorn University, Chulalongkorn Hospital, Bangkok,

Thailand. He trained at Mahidol University and Ramathibodi Hospital

in Thailand and continued his post-graduate training specialising in

Endocrinology and Metabolism in the USA at The Diabetes Institutes, Eastern

Virginia Medical School, Virginia and at the University of Massachusetts

Medical Center, Massachusetts respectively.

Associate Professor Suwanwalaikorn’s academic and research interest have

been focused in the areas of diabetes and thyroid disease, both of which

he has published work in academic journals. In addition to his academic

research interests Associate Professor Suwanwalaikorn is an active member

of a number of professional medical societies pertinent to his interest in

endocrinology and diabetes including The Endocrine Society of Thailand,

The ASEAN Federation of Endocrine Society (AFES), The American Diabetes

Association (ADA) as well as The Royal College of Physicians of Thailand.

Associate Professor Suwanwalaikorn is also a member of the Thai Medical

Council.

Division of

Endocrinology and

Metabolism

Chulalongkorn

University, Bangkok,

Thailand

1 0 | A S I A N I N T E R C H A N G E O N D I A B E T E S

Chaicharn Deerochanawong

Lecture:

• Diabetes in Asia: What is different from the west?

Chaicharn Deerochanawong holds a position as a Professor of Medicine in

Diabetes and Endocrinology Unit at Rajavithi Hospital, College of Medicine,

Rangsit University, Bangkok, Thailand. Currently, he is Scientific Chairman

of the Endocrine Society of Thailand, Secretary and committee member of

the Thai Obesity Association, and a committee member of both the Thai

Atherosclerosis Association and the Royal College of Physicians of Thailand.

Prof. Chaicharn Deerochanawong undertook his clinical and research training

in Diabetes and Endocrinology at the University of Newcastle Upon Tyne,

United Kingdom.

He graduated his Medicine from Chulalongkorn University.In 1992, he

received grant fellowship of Diabetes and Endocrinology in UK by British

Council and in 1996, he received ‘Distinguished research award from ‘Thai

Endocrine Society’. His scientific interests lie in both clinical and research

particularly in the field of diabetes especially diabetes in pregnancy, obesity

and dyslipidaemia.

He was the Principle Investigator Thailand site of HAPO study

(Hyperglycemia and Adverse Pregnancy Outcomes). During his career,

Prof. Chaicharn Deerochanawong has presented and lectured at numerous

meetings both local and international and contributed to many publications,

including over 80 scientific articles.

Rajavithi Hospital

College of Medicine

Bangkok, Thailand

3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 1 1

Richard E. Pratley

Lectures:

• Management of hyperglycemia in type 2 diabetes: Update on

novel trends and developments

• Update on DPP4 inhibition in T2DM: Implications from recent

and ongoing trials

Dr. Richard Pratley is the Medical Director of the Florida Hospital Diabetes

Institute (FHDI). He is also Senior Faculty at the Translational Research

Institute for Metabolism and Diabetes, as well as a Professor at the Sanford-

Burnham Medical Research Institute at Lake Nona in Orlando, Florida.

Dr. Pratley has served as Head of the Diabetes and Metabolism Unit of

the National Institutes of Health Clinical Diabetes and Nutrition Section

in Phoenix, Arizona. He then took a position as Senior Director in the

Cardiovascular and Metabolism Therapeutic Area at Novartis Pharmaceuticals

where he worked on the clinical development of new drugs for diabetes. From

2004 to 2011, Dr. Pratley was the Director of University of Vermont’s Diabetes

and Metabolism Translational Medicine Unit and a Professor at their College

of Medicine. There he led many large-scale investigations, including NIH and

pharmaceutical company sponsored studies.

As a member of the American Diabetes Association, the European

Association for the Study of Diabetes and The Obesity Society, Dr. Pratley

continues his active involvement in the professional community. The Henry

Christian Award for Excellence in Clinical Research from the American

Federation for Clinical Research Foundation was awarded in recognition of

his work. He regularly presents at national and international meetings, has

written over 150 peer-reviewed articles and is a Principal Investigator for both

NIH and pharmaceutical company sponsored trials in diabetes. He is on the

editorial boards of Diabetes Care and Current Diabetes Reports and acts

as an ad hoc reviewer for many journals, including the American Journal of

Cardiology and Diabetes.

Dr. Pratley is a graduate of Wayne State University School of Medicine

in Detroit, Michigan, and trained in internal medicine at the University of

Michigan in Ann Arbor. He completed Fellowship training in geriatrics and

gerontology at the University of Michigan, Johns Hopkins University, and the

National Institutes of Health (NIH) National Institute on Aging in Baltimore,

Maryland. His current research interests include the prevention of diabetes,

improving the care for persons with diabetes, developing new drugs to treat

and prevent diabetes and its complications and understanding the role of the

fat cell in increasing the risk for diabetes and heart disease.

Florida Hospital

Diabetes Institute

Orlando, FL, USA


Michael Mark

Lectures:

• Need for ongoing clinical innovation in management of T2DM - A

closer look at the development process of new entities

• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty

Substrate” Hypothesis

Dr. Michael Mark, PhD is the Vice President and Global Head of

CardioMetabolic Diseases Research at Boehringer Ingelheim, Germany. In

this role, he is responsible for the research and development of innovative

treatments for cardiovascular and metabolic diseases including type 2

diabetes mellitus, obesity, NASH and diabetic microvascular complications

like eye diseases as well as kidney diseases. Educated as pharmacist

Dr Mark is holding a Ph.D. degree in Pharmacology from the University of

Tuebingen in Germany.

Dr Mark has more than 30 years experience in the pharmaceutical industry.

Early in his career, Dr Mark contributed to the discovery and development

of repaglinide, an approved treatment of type 2 diabetes. He pioneered the

discovery of the DPP-4 inhibitor linagliptin (Trajenta) and was instrumental

in the initiation of the preclinical work for the SGLT2 inhibitor empagliflozin

(Jardiance), both compounds globally launched and marketed. Together with

his team he developed a competitive portfolio for cardiometabolic treatment

options with various preclinical and several clinical developments projects

currently ongoing.

Dr Mark has been appointed as Project Coordinator for SUMMIT, an

Innovative Medicines Initiative (IMI)-sponsored European consortium of

19 academic centers and 6 major pharmaceutical partners, which aims to

identify and characterize novel biomarkers and genetic markers for diabetic

complications. Dr Mark authored many peer-reviewed publications and

meeting contributions and also various book chapters. In addition he holds

numerous patents.

Boehringer Ingelheim

– Cardiometabolic

Diseases Research


Per-Henrik Groop

Lecture:

• Understanding Diabetes Kidney Disease: What are the best

options for clinical management?

Per-Henrik Groop, MD, DMSc, FRCPE is currently a Professor of Nephrology

(Chair) at the University of Helsinki, Chief Physician at the Division of

Nephrology, Helsinki University Central Hospital and Principal Investigator

of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan

Research Center in Helsinki, Finland. He also acts as a Professor at the Baker

Heart & Diabetes Institute in Melbourne, Australia. He graduated from the

University of Helsinki in 1982 and he defended his thesis on “The relationship

between GIP and beta-cell function in man” at the same university in 1989.

After postdoctoral studies at the Guy’s Hospital, University of London, under

Professor Giancarlo Viberti, he returned to Helsinki to work as a Consultant

of Nephrology.

His research is focused on the dissection of the pathogenesis of diabetic

complications with special emphasis on diabetic nephropathy. In order to

provide a unique set of clinical resources with high power to identify genes

and genetic variants associated with diabetic complications, he initiated

the large, nation-wide FinnDiane Study in 1997. To date this landmark study

comprises 8400 patients with type 1 diabetes and their family members

recruited via a comprehensive network of 92 hospitals and health care

centers throughout Finland. The FinnDiane Research Group represents an

inter-disciplinary team of 45 scientists, post-graduate students and other

personnel.

University of Helsinki

Helsinki, Finland


Notes

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Project Managers:

Lieke van Heugten: +31 6 27 08 05 86Iris van Kaam: +31 6 22 74 05 10

MEDCON International

The program is managed by MEDCON International bv under the

auspices of the PACE Foundation. For more information please

contact MEDCON International at: Tel + 31 (0)23 5317 357 or e-mail

[email protected], P.O. box 916, 2003 RX, Haarlem,

The Netherlands.

PACE Foundation

c/o MEDCON International, P.O. Box 916, 2003 RX Haarlem,

The Netherlands, www.pace-cme.org

Supported by an educational grant from Boehringer Ingelheim

program - pace-cme · 2016. 12. 24. · centara grand & bangkok convention centre at...

Documents